Targeting the TNF-α pathway in sarcoidosis

Bibliography

• Muller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998;12(3):716-38
   PubMed Web of Science ®Google Scholar
• Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160(2):736-55
   PubMedGoogle Scholar
• Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology. Respir Res 2006;7:125. Published online 11 October 2006, doi:10.1186/1465-9921-7-125
   PubMed Web of Science ®Google Scholar
• Sheehan KC, Pinckard JK, Arthur CD, Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med 1995;181(2):607-17
   PubMed Web of Science ®Google Scholar
• Agostini C, Zambello R, Sancetta R, Expression of tumor necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease. Am J Respir Crit Care Med 1996;153(4 Pt 1):1359-67
   PubMed Web of Science ®Google Scholar
• Lukacs NW, Chensue SW, Strieter RM, Inflammatory granuloma formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-1. J Immunol 1994;152(12):5883-9
   PubMed Web of Science ®Google Scholar
• Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990;115(1):36-42
   PubMed Web of Science ®Google Scholar
• Semenzato G, Bortoli M, Brunetta E, Agostini C. Immunology and pathophysiology. In: Drent M, Costabel U, editors, Sarcoidosis. Eur Respir Mon 2005;10:49-63
   Google Scholar
• Bachwich PR, Lynch JP III, Larrick J, Tumor necrosis factor production by human sarcoid alveolar macrophages. Am J Pathol 1986;125(3):421-5
   PubMed Web of Science ®Google Scholar
• Muller-Quernheim J, Pfeifer S, Mannel D, Lung-restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am Rev Respir Dis 1992;145(1):187-92
   PubMedGoogle Scholar
• Spatafora M, Merendino A, Chiappara G, Lung compartmentalization of increased TNF releasing ability by mononuclear phagocytes in pulmonary sarcoidosis. Chest 1989;96(3):542-9
   PubMed Web of Science ®Google Scholar
• Zheng L, Teschler H, Guzman J, Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. Am J Respir Crit Care Med 1995;152(3):1061-6
   PubMed Web of Science ®Google Scholar
• Ishioka S, Saito T, Hiyama K, Increased expression of tumor necrosis factor-alpha, interleukin-6, platelet-derived growth factor-B and granulocyte-macrophage colony-stimulating factor mRNA in cells of bronchoalveolar lavage fluids from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1996;13(2):139-45
   PubMed Web of Science ®Google Scholar
• Armstrong L, Foley NM, Millar AB. Inter-relationship between tumour necrosis factor-alpha (TNF-alpha) and TNF soluble receptors in pulmonary sarcoidosis. Thorax 1999;54(6):524-30
   PubMed Web of Science ®Google Scholar
• Menestrina F, Lestani M, Mombello A, Transbronchial biopsy in sarcoidosis: the role of immunohistochemical analysis for granuloma detection. Sarcoidosis 1992;9(2):95-100
   PubMedGoogle Scholar
• Shikama Y, Kobayashi K, Kasahara K, Granuloma formation by artificial microparticles in vitro. Macrophages and monokines play a critical role in granuloma formation. Am J Pathol 1989;134(6):1189-99
   PubMed Web of Science ®Google Scholar
• Kasahara K, Kobayashi K, Shikama Y, The role of monokines in granuloma formation in mice: the ability of interleukin 1 and tumor necrosis factor-alpha to induce lung granulomas. Clin Immunol Immunopathol 1989;51(3):419-25
   PubMedGoogle Scholar
• Moodley YP, Dorasamy T, Venketasamy S, Correlation of CD4:CD8 ratio and tumour necrosis factor (TNF)alpha levels in induced sputum with bronchoalveolar lavage fluid in pulmonary sarcoidosis. Thorax 2000;55(8):696-9
   PubMed Web of Science ®Google Scholar
• Luisetti M, Beretta A, Casali L. Genetic aspects in sarcoidosis. Eur Respir J 2000;16(4):768-80
   PubMed Web of Science ®Google Scholar
• Somoskovi A, Zissel G, Seitzer U, Polymorphisms at position -308 in the promoter region of the TNF-alpha and in the first intron of the TNF-beta genes and spontaneous and lipopolysaccharide-induced TNF-alpha release in sarcoidosis. Cytokine 1999;11(11):882-7
   PubMed Web of Science ®Google Scholar
• Seitzer U, Swider C, Stuber F, Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997;9(10):787-90
   PubMed Web of Science ®Google Scholar
• Swider C, Schnittger L, Bogunia-Kubik K, TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. Eur Cytokine Netw 1999;10(2):143-6
   PubMed Web of Science ®Google Scholar
• Grutters JC, Sato H, Pantelidis P, Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002;165(8):1119-24
   PubMed Web of Science ®Google Scholar
• Yamaguchi E, Itoh A, Hizawa N, Kawakami Y. The gene polymorphism of tumor necrosis factor-beta, but not that of tumor necrosis factor-alpha, is associated with the prognosis of sarcoidosis. Chest 2001;119(3):753-61
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19(3):185-90
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Benner UK, Zissel G, Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997;156(5):1586-92
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Fitschen J, Martinet N, Serum level of soluble tumour necrosis factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis. J Intern Med 2000;248(1):33-41
   PubMed Web of Science ®Google Scholar
• Kieszko R, Krawczyk P, Chocholska S, Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis. Respir Med 2007;101(3):645-54
   PubMed Web of Science ®Google Scholar
• Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172(1):391-4
   PubMed Web of Science ®Google Scholar
• Funk JO, Ernst M, Schonharting MM, Zabel P. Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Int J Immunopharmacol 1995;17(12):1007-16
   PubMed Web of Science ®Google Scholar
• Zabel P, Wolter DT, Schonharting MM, Schade UF. Oxpentifylline in endotoxaemia. Lancet 1989;2(8678-8679):1474-7
   PubMed Web of Science ®Google Scholar
• Sawyer RT, Fontenot AP, Barnes TA, Beryllium-induced TNF-alpha production is transcription-dependent in chronic beryllium disease. Am J Respir Cell Mol Biol 2007;36(2):191-200
   PubMed Web of Science ®Google Scholar
• Marques LJ, Zheng L, Poulakis N, Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999;159(2):508-11
   PubMed Web of Science ®Google Scholar
• Tong Z, Dai H, Chen B, Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 2003;124(4):1526-32
   PubMed Web of Science ®Google Scholar
• Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997;155(5):1665-9
   PubMed Web of Science ®Google Scholar
• Perri AJ III, Hsu S. A review of thalidomide's history and current dermatological applications. Dermatol Online J 2003;9(3):5
   PubMedGoogle Scholar
• Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000;108(6):487-95
   PubMed Web of Science ®Google Scholar
• Tseng S, Pak G, Washenik K, Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35(6):969-79
   PubMed Web of Science ®Google Scholar
• Moller DR. Treatment of sarcoidosis: from a basic science point of view. J Intern Med 2003;253(1):31-40
   PubMed Web of Science ®Google Scholar
• Moller DR, Wysocka M, Greenlee BM, Inhibition of IL-12 production by thalidomide. J Immunol 1997;159(10):5157-61
   PubMed Web of Science ®Google Scholar
• Tavares JL, Wangoo A, Dilworth P, Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997;91(1):31-9
   PubMed Web of Science ®Google Scholar
• Ye Q, Chen B, Tong Z, Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 2006;28(4):824-31
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Teirstein AS, Thalidomide for chronic sarcoidosis. Chest 2002;122(1):227-32
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. Am J Clin Dermatol 2004;5(6):385-94
   PubMed Web of Science ®Google Scholar
• Carlesimo M, Giustini S, Rossi A, Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995;32(5 Pt 2):866-9
   PubMed Web of Science ®Google Scholar
• Hammond ER, Kaplin AI, Kerr DA. Thalidomide for acute treatment of neurosarcoidosis. Spinal Cord 2007;45(12):802-3
   PubMed Web of Science ®Google Scholar
• Nguyen YT, Dupuy A, Cordoliani F, Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004;50(2):235-41
   PubMed Web of Science ®Google Scholar
• Judson MA, Silvestri J, Hartung C, The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23(1):51-7
   PubMed Web of Science ®Google Scholar
• Antoniu SA, Mihaltan F, Ulmeanu R. Anti-TNF-alpha therapies in chronic obstructive pulmonary diseases. Expert Opin Investig Drugs 2008;17(8):1203-11
   PubMed Web of Science ®Google Scholar
• Nanda S, Bathon JM. Etanercept: a clinical review of current and emerging indications. Expert Opin Pharmacother 2004;5(5):1175-86
   PubMed Web of Science ®Google Scholar
• Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 2007;8(13):2089-107
   PubMed Web of Science ®Google Scholar
• Enbrel. European Public Assessment Report for authorised medicinal products for human use. London UK: European Medicines Agency (EMEA). (2007). Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrel.htm [Last accesssed 31 October 2009]
   Google Scholar
• Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003;30(8):1864-7
   PubMed Web of Science ®Google Scholar
• Tuchinda C, Wong HK. Etanercept for chronic progressive cutaneous sarcoidosis. J Drugs Dermatol 2006;5(6):538-40
   PubMedGoogle Scholar
• Baughman RP, Lower EE, Bradley DA, Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128(2):1062-47
   PubMed Web of Science ®Google Scholar
• Utz JP, Limper AH, Kalra S, Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124(1):177-85
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18(1):70-4
   PubMed Web of Science ®Google Scholar
• Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004;117(4):277-9
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127(3):1064-71
   PubMed Web of Science ®Google Scholar
• Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol 2005;141(7):910-11
   PubMedGoogle Scholar
• Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004;63(3):318-20
   PubMed Web of Science ®Google Scholar
• Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003;124(5):2028-31
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP, A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23(3):201-8
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174(7):795-802
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008;25(2):76-89
   PubMed Web of Science ®Google Scholar
• Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006;25(4):596-7
   PubMed Web of Science ®Google Scholar